Synonyms: MCLA 158
Petosemtamab (Anti-EGFR/LGR5) is a highly potent bispecific antibody against EGFR (Kd 0.22 nM) and LGR5 (Kd 0.86 nM). It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | GPR | Others |
|---|---|---|---|
| AZD1981 | 2 | ||
| NF-56-EJ40 | 0 | ||
| ML401 | 0 | ||
| PH-064 | 0 | ||
| NE 52-QQ57 | 1 | IL-1β,TNF-α,PGE2 | |
| NIBR189 | 0 | ||
| JMS-17-2 | 3 | ||
| OC000459 | 0 | ||
| Kisspeptin-10 (human) | 0 | ||
| CLP-3094 | 0 | AR |
| Description |
Petosemtamab (Anti-EGFR/LGR5) is a highly potent bispecific antibody against EGFR (Kd 0.22 nM) and LGR5 (Kd 0.86 nM). It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD.
|
|---|
| CAS No. | 2213450-26-9 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.